Purpose . The purpose of this paper is to evaluate a new PET tracer 64 Cu-NODAGA-c(RGDyK) for imaging of tumor angiogenesis using gene expression of angiogenesis markers as reference and to estimate radiation dosimetry for humans. Procedures . Nude mice with human neuroendocrine tumor xenografts (H727) were administered 64 Cu-NODAGA-c(RGDyK) i.v. for study of biodistribution as well as for dynamic PET. Gene expression of angiogenesis markers integrin , integrin , and VEGF-A were analyzed using QPCR and correlated to the tracer uptake in the tumors (%ID/g). From biodistribution data human radiation-absorbed doses were estimated using OLINDA/EXM. Results . Tumor uptake was 1.2%ID/g with strong correlations between gene expression and tracer uptake, for integrin , integrin and VEGF-A (all ). The whole body effective dose for humans was estimated to be 0.038 and 0.029 mSv/MBq for females and males, respectively, with highest absorbed dose in bladder wall. Conclusion . 64 Cu-NODAGA-c(RGDyK) is a promising new angiogenesis PET tracer with potential for human use.
Oxboel, J., Schjoeth-Eskesen, C., El-Ali, H. H., Madsen, J., & Kjaer, A. (2012). 64 Cu-NODAGA-c(RGDyK) Is a Promising New Angiogenesis PET Tracer: Correlation between Tumor Uptake and Integrin Expression in Human Neuroendocrine Tumor Xenografts . International Journal of Molecular Imaging, 2012, 1–11. https://doi.org/10.1155/2012/379807